Company news

LENZ Therapeutics, Inc. news in 2024

LENZ Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

LENZ Therapeutics Reports Third Quarter 2024 Financial Results

November 5, 2024

LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024

October 29, 2024

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

October 26, 2024

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

October 20, 2024

LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences

September 29, 2024

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

August 13, 2024

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

August 11, 2024

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

August 6, 2024

LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital

July 14, 2024

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

June 9, 2024

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2024

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

April 30, 2024

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

April 2, 2024

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

April 1, 2024

Calls in 2024

Decks in 2024